Logo.png
Acute Bacterial Skin and Skin Structure Infections Pipeline Featuring Plethora of Emerging Drugs, Key Companies 
May 24, 2021 20:30 ET | DelveInsight Business Research LLP
Los Angeles, USA, May 24, 2021 (GLOBE NEWSWIRE) -- Acute Bacterial Skin and Skin Structure Infections Pipeline Featuring Plethora of Emerging Drugs, Key Companies  Ceftobiprole Medocaril under...
Melinta Therapeutics
Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe
March 08, 2018 07:00 ET | Melinta Therapeutics
NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics
Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina
February 20, 2018 07:00 ET | Melinta Therapeutics
NEW HAVEN, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics
Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States
January 29, 2018 07:00 ET | Melinta Therapeutics
– Approved for adult patients with acute bacterial skin and skin structure infections (ABSSSI) – – Provides coverage of gram-positive and gram-negative pathogens; only FDA-approved fluoroquinolone...
Melinta Therapeutics
Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States
October 30, 2017 08:01 ET | Melinta Therapeutics
NEW HAVEN, Conn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...
Melinta Therapeutics
Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek
October 04, 2017 13:13 ET | Melinta Therapeutics
NEW HAVEN, Conn., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics
Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
June 19, 2017 16:30 ET | Melinta Therapeutics
- Baxdela offers a new option for treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) including hospital-treated skin infections in oral and IV formulations as...
LOGO JPG.jpg
Cempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
February 28, 2017 06:45 ET | Cempra, Inc.
—Management to host webcast and conference call today at 8:45 a.m. ET— CHAPEL HILL, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company...
LOGO JPG.jpg
Cempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI
February 24, 2017 07:00 ET | Cempra, Inc.
—Fusidic acid met primary endpoint and secondary efficacy endpoints— —Fusidic acid well tolerated in the study— CHAPEL HILL, N.C., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a...
Melinta Therapeutics
Melinta Therapeutics’ Baxdela™ to be Featured in Six Poster Presentations at IDWeek 2016™
October 26, 2016 08:00 ET | Melinta Therapeutics
NEW ORLEANS, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company exclusively focused on developing novel antibiotics to treat serious bacterial infections,...